Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone for COVID-19 Related Severe ARDS
NCT04653831Phase 2Completed
- Sponsor
- Soroka University Medical Center
- Start
- Nov 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute respiratory distress syndrome (ARDS) comparing Pirfenidone Treatment with Standard of Care - Control (2 arms). Primary endpoints: Ventilation free days to day 28 and Severe adverse events rate at 1 year. Started Nov 2020; status: completed.
02
Drugs
pirfenidone
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04653831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04653831.